PDG79 WAS THE EVIDENCE BASE FOR YESCARTA AND KYMRIAH SUFFICIENT TO JUSTIFY THEIR COST AND SECURE PATIENT ACCESS ACROSS 5 MARKETS?
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.1092
https://www.valueinhealthjournal.com/article/S1098-3015(19)33470-9/fulltext
Title :
PDG79 WAS THE EVIDENCE BASE FOR YESCARTA AND KYMRIAH SUFFICIENT TO JUSTIFY THEIR COST AND SECURE PATIENT ACCESS ACROSS 5 MARKETS?
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)33470-9&doi=10.1016/j.jval.2019.09.1092
First page :
Section Title :
Open access? :
No
Section Order :
10962